- Home
- HUHU vs PRLD Comparison
HUHU vs PRLD Comparison
Compare HUHU & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- PRLD
- Stock Information
- Founded
- HUHU 2015
- PRLD 2016
- Country
- HUHU China
- PRLD United States
- Employees
- HUHU N/A
- PRLD N/A
- Industry
- HUHU
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- HUHU
- PRLD Health Care
- Exchange
- HUHU NYSE
- PRLD Nasdaq
- Market Cap
- HUHU 91.5M
- PRLD 73.7M
- IPO Year
- HUHU 2024
- PRLD 2020
- Fundamental
- Price
- HUHU $4.70
- PRLD $0.88
- Analyst Decision
- HUHU
- PRLD Strong Buy
- Analyst Count
- HUHU 0
- PRLD 2
- Target Price
- HUHU N/A
- PRLD $4.50
- AVG Volume (30 Days)
- HUHU 43.5K
- PRLD 277.7K
- Earning Date
- HUHU 02-22-2025
- PRLD 05-06-2025
- Dividend Yield
- HUHU N/A
- PRLD N/A
- EPS Growth
- HUHU 13.14
- PRLD N/A
- EPS
- HUHU 0.08
- PRLD N/A
- Revenue
- HUHU $17,492,735.00
- PRLD $7,000,000.00
- Revenue This Year
- HUHU N/A
- PRLD N/A
- Revenue Next Year
- HUHU N/A
- PRLD N/A
- P/E Ratio
- HUHU $55.78
- PRLD N/A
- Revenue Growth
- HUHU 33.03
- PRLD N/A
- 52 Week Low
- HUHU $2.95
- PRLD $0.61
- 52 Week High
- HUHU $9.89
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- PRLD 60.39
- Support Level
- HUHU N/A
- PRLD $0.71
- Resistance Level
- HUHU N/A
- PRLD $0.86
- Average True Range (ATR)
- HUHU 0.00
- PRLD 0.08
- MACD
- HUHU 0.00
- PRLD 0.03
- Stochastic Oscillator
- HUHU 0.00
- PRLD 80.38
About HUHU HUHUTECH INTL GROUP INC
HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.